FYR Bio names COO as EV‑Omics scales, signaling demand for ABB‑style lab automation

FYR Bio names operations chief as EV‑omics platform scales

Operational scaling at FYR Bio signals growing demand for laboratory automation and quality systems suppliers, a trend that matters for companies such as ABB that serve the life‑sciences and bioprocessing sectors. FYR appoints Barbara K. Zehentner as chief operating officer to lead execution as the company expands its EV‑Omics (EVO) platform, lab capacity and partner programs across neuroscience and oncology. The move underlines FYR’s emphasis on inspection readiness, CLIA/CAP compliance and automation to deliver reproducible multiomic outputs at scale.

The hire centres on building multi‑site, high‑complexity laboratory operations and implementing robust quality management, areas where industrial automation and process control vendors play an increasing role. FYR’s stated priorities — smart automation, disciplined execution and inspection readiness — create technical and integration opportunities for suppliers of laboratory robotics, workflow automation and digital quality systems. Firms that provide end‑to‑end automation for sample handling, high‑throughput sequencing and regulated analytics stand to support biotech companies moving from pilot studies to routine, certified service delivery.

For ABB and similar companies, the FYR development reflects a broader shift in diagnostics and drug‑development workflows toward modular, scalable automation and tighter interoperability between instrumentation and informatics. As small biotech labs seek to reduce manual steps, shorten turnaround times and document compliance, demand rises for systems that integrate physical automation with software for data integrity and audit readiness. FYR’s emphasis on AI‑enabled multiomic data and platform throughput also highlights the convergence of robotics, analytics and lab informatics in establishing commercial, regulated services.

Experienced operations leader joins to drive execution

Zehentner brings more than two decades of building and leading CLIA/CAP laboratory operations, multi‑site workflows, automation and inspection readiness. She most recently serves as COO at Molecular Testing Labs and was previously VP of Molecular Laboratory Operations at Adaptive Biotechnologies, where she directed high‑throughput next‑generation sequencing operations.

Platform focus and partner strategy

FYR’s EVO platform uses SPARCs™ to enrich extracellular vesicles from diseased cells and assess cellular proteins and nucleic acids, producing AI‑enabled multiomic data intended to support diagnostics, biomarker discovery, clinical trial design and drug development. The company frames its expansion as supporting CLIA/CAP‑certified services for biopharma, academic and clinical collaborators.